Search

Your search keyword '"(Zadro, R"' showing total 200 results
Start Over Author "(Zadro, R"
200 results on '"(Zadro, R"'

1. Induction of adipocytic differentiation in myxoid liposarcoma: new approaches to improve the effectiveness of the available therapies

Author

Meroni, M, Craparotta, I, Mannarino, L, Zadro, R, Morosi, L, Matteo, C, Bello, E, Ubezio, P, Zucchetti, M, Renne, S, D’Incalci, M, Frapolli, R, M. Meroni, I. Craparotta, L. Mannarino, R. Zadro, L. Morosi, C. Matteo, E. Bello, P. Ubezio, M. Zucchetti, S. L. Renne, M. D’Incalci, R. Frapolli, Meroni, M, Craparotta, I, Mannarino, L, Zadro, R, Morosi, L, Matteo, C, Bello, E, Ubezio, P, Zucchetti, M, Renne, S, D’Incalci, M, Frapolli, R, M. Meroni, I. Craparotta, L. Mannarino, R. Zadro, L. Morosi, C. Matteo, E. Bello, P. Ubezio, M. Zucchetti, S. L. Renne, M. D’Incalci, and R. Frapolli

Published
2024

2. Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer

Author

Paracchini, L, Mannarino, L, Romualdi, C, Zadro, R, Beltrame, L, Nerini, I, Zola, P, Laudani, M, Pagano, E, Giordano, L, Fruscio, R, Landoni, F, Franceschi, S, Dalessandro, M, Canzonieri, V, Bocciolone, L, Lorusso, D, Bosetti, C, Raspagliesi, F, Garassino, I, D'Incalci, M, Marchini, S, Grassi, T, Bianchi, T, Cursano, G, Mangili, G, Scambia, G, Marchetti, C, Boldorini, R, De Rosa, G, Ferrero, A, Feyles, E, Goia, M, Manini, C, Orlassino, R, Surico, D, Volante, M, Greggi, S, Jaconi, M, Bella, C, Vitobello, D, di Loreto, C, Pizzolitto, S, Zanconati, F, Ciccone, G, Armaroli, P, Larato, C, Rizzolo, R, Paracchini L., Mannarino L., Romualdi C., Zadro R., Beltrame L., Nerini I. F., Zola P., Laudani M. E., Pagano E., Giordano L., Fruscio R., Landoni F., Franceschi S., Dalessandro M. L., Canzonieri V., Bocciolone L., Lorusso D., Bosetti C., Raspagliesi F., Garassino I. M. G., D'Incalci M., Marchini S., Grassi T., Bianchi T., Cursano G., Mangili G., Scambia G., Marchetti C., Boldorini R., De Rosa G., Ferrero A., Feyles E., Goia M., Manini C., Orlassino R., Surico D., Volante M., Greggi S., Jaconi M., Bella C. D., Vitobello D., di Loreto C., Pizzolitto S., Zanconati F., Ciccone G., Armaroli P., Larato C., Rizzolo R., Paracchini, L, Mannarino, L, Romualdi, C, Zadro, R, Beltrame, L, Nerini, I, Zola, P, Laudani, M, Pagano, E, Giordano, L, Fruscio, R, Landoni, F, Franceschi, S, Dalessandro, M, Canzonieri, V, Bocciolone, L, Lorusso, D, Bosetti, C, Raspagliesi, F, Garassino, I, D'Incalci, M, Marchini, S, Grassi, T, Bianchi, T, Cursano, G, Mangili, G, Scambia, G, Marchetti, C, Boldorini, R, De Rosa, G, Ferrero, A, Feyles, E, Goia, M, Manini, C, Orlassino, R, Surico, D, Volante, M, Greggi, S, Jaconi, M, Bella, C, Vitobello, D, di Loreto, C, Pizzolitto, S, Zanconati, F, Ciccone, G, Armaroli, P, Larato, C, Rizzolo, R, Paracchini L., Mannarino L., Romualdi C., Zadro R., Beltrame L., Nerini I. F., Zola P., Laudani M. E., Pagano E., Giordano L., Fruscio R., Landoni F., Franceschi S., Dalessandro M. L., Canzonieri V., Bocciolone L., Lorusso D., Bosetti C., Raspagliesi F., Garassino I. M. G., D'Incalci M., Marchini S., Grassi T., Bianchi T., Cursano G., Mangili G., Scambia G., Marchetti C., Boldorini R., De Rosa G., Ferrero A., Feyles E., Goia M., Manini C., Orlassino R., Surico D., Volante M., Greggi S., Jaconi M., Bella C. D., Vitobello D., di Loreto C., Pizzolitto S., Zanconati F., Ciccone G., Armaroli P., Larato C., and Rizzolo R.

Abstract

Late diagnosis and the lack of screening methods for early detection define high-grade serous ovarian cancer (HGSOC) as the gynecological malignancy with the highest mortality rate. In the work presented here, we investigated a retrospective and multicentric cohort of 250 archival Papanicolaou (Pap) test smears collected during routine gynecological screening. Samples were taken at different time points (from 1 month to 13.5 years before diagnosis) from 113 presymptomatic women who were subsequently diagnosed with HGSOC (pre-HGSOC) and from 77 healthy women. Genome instability was detected through low-pass whole-genome sequencing of DNA derived from Pap test samples in terms of copy number profile abnormality (CPA). CPA values of DNA extracted from Pap test samples from pre-HGSOC women were substantially higher than those in samples from healthy women. Consistently with the longitudinal analysis of clonal pathogenic TP53 mutations, this assay could detect HGSOC presence up to 9 years before diagnosis. This finding confirms the continual shedding of tumor cells from fimbriae toward the endocervical canal, suggesting a new path for the early diagnosis of HGSOC. We integrated the CPA score into the EVA (early ovarian cancer) test, the sensitivity of which was 75% (95% CI, 64.97 to 85.79), the specificity 96% (95% CI, 88.35 to 100.00), and the accuracy 81%. This proof-of-principle study indicates that the early diagnosis of HGSOC is feasible through the analysis of genomic alterations in DNA from endocervical smears.

Published
2023

3. Standardization of molecular monitoring of CML : results and recommendations from the European treatment and outcome study

Author

White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, Barbany G, Cayuela JM, Cerveira N, Cochaux P, Colomer D, Coriu D, Diamond J, Dietz C, Dulucq S, Engvall M, Franke GN, Gineikiene-Valentine E, Gniot M, Gómez-Casares MT, Gottardi E, Hayden C, Hayette S, Hedblom A, Ilea A, Izzo B, Jiménez-Velasco A, Jurcek T, Kairisto V, Langabeer SE, Lion T, Meggyesi N, Mešanović S, Mihok L, Mitterbauer-Hohendanner G, Moeckel S, Naumann N, Nibourel O, Oppliger Leibundgut E, Panayiotidis P, Podgornik H, Pott C, Rapado I, Rose SJ, Schäfer V, Touloumenidou T, Veigaard C, Venniker-Punt B, Venturi C, Vigneri P, Vorkinn I, Wilkinson E, Zadro R, Zawada M, Zizkova H, Müller MC, Saussele S, Ernst T, Machova Polakova K, Hochhaus A, Cross NCPa 62, Andreas Hochhaus 52, Nicholas C P Cross, White, He, Salmon, M, Albano, F, Andersen, Csa, Balabanov, S, Balatzenko, G, Barbany, G, Cayuela, Jm, Cerveira, N, Cochaux, P, Colomer, D, Coriu, D, Diamond, J, Dietz, C, Dulucq, S, Engvall, M, Franke, Gn, Gineikiene-Valentine, E, Gniot, M, Gómez-Casares, Mt, Gottardi, E, Hayden, C, Hayette, S, Hedblom, A, Ilea, A, Izzo, B, Jiménez-Velasco, A, Jurcek, T, Kairisto, V, Langabeer, Se, Lion, T, Meggyesi, N, Mešanović, S, Mihok, L, Mitterbauer-Hohendanner, G, Moeckel, S, Naumann, N, Nibourel, O, Oppliger Leibundgut, E, Panayiotidis, P, Podgornik, H, Pott, C, Rapado, I, Rose, Sj, Schäfer, V, Touloumenidou, T, Veigaard, C, Venniker-Punt, B, Venturi, C, Vigneri, P, Vorkinn, I, Wilkinson, E, Zadro, R, Zawada, M, Zizkova, H, Müller, Mc, Saussele, S, Ernst, T, Machova Polakova, K, Hochhaus, A, Cross NCPa, 62, Andreas Hochhaus, 52, and Nicholas C, P Cross

Subjects
Cancer Research, Cancer och onkologi, Fatigue Syndrome, Chronic, Fusion Proteins, bcr-abl, 610 Medicine & health, Hematology, Reference Standards, Treatment Outcome, Oncology, hemic and lymphatic diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Cancer and Oncology, Humans, Hematologi
Abstract

Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1IS and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance.

Published
2022
Full Text
View/download PDF

4. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Author

White, H.E. Salmon, M. Albano, F. Andersen, C.S.A. Balabanov, S. Balatzenko, G. Barbany, G. Cayuela, J.-M. Cerveira, N. Cochaux, P. Colomer, D. Coriu, D. Diamond, J. Dietz, C. Dulucq, S. Engvall, M. Franke, G.N. Gineikiene-Valentine, E. Gniot, M. Gómez-Casares, M.T. Gottardi, E. Hayden, C. Hayette, S. Hedblom, A. Ilea, A. Izzo, B. Jiménez-Velasco, A. Jurcek, T. Kairisto, V. Langabeer, S.E. Lion, T. Meggyesi, N. Mešanović, S. Mihok, L. Mitterbauer-Hohendanner, G. Moeckel, S. Naumann, N. Nibourel, O. Oppliger Leibundgut, E. Panayiotidis, P. Podgornik, H. Pott, C. Rapado, I. Rose, S.J. Schäfer, V. Touloumenidou, T. Veigaard, C. Venniker-Punt, B. Venturi, C. Vigneri, P. Vorkinn, I. Wilkinson, E. Zadro, R. Zawada, M. Zizkova, H. Müller, M.C. Saussele, S. Ernst, T. Machova Polakova, K. Hochhaus, A. Cross, N.C.P. and White, H.E. Salmon, M. Albano, F. Andersen, C.S.A. Balabanov, S. Balatzenko, G. Barbany, G. Cayuela, J.-M. Cerveira, N. Cochaux, P. Colomer, D. Coriu, D. Diamond, J. Dietz, C. Dulucq, S. Engvall, M. Franke, G.N. Gineikiene-Valentine, E. Gniot, M. Gómez-Casares, M.T. Gottardi, E. Hayden, C. Hayette, S. Hedblom, A. Ilea, A. Izzo, B. Jiménez-Velasco, A. Jurcek, T. Kairisto, V. Langabeer, S.E. Lion, T. Meggyesi, N. Mešanović, S. Mihok, L. Mitterbauer-Hohendanner, G. Moeckel, S. Naumann, N. Nibourel, O. Oppliger Leibundgut, E. Panayiotidis, P. Podgornik, H. Pott, C. Rapado, I. Rose, S.J. Schäfer, V. Touloumenidou, T. Veigaard, C. Venniker-Punt, B. Venturi, C. Vigneri, P. Vorkinn, I. Wilkinson, E. Zadro, R. Zawada, M. Zizkova, H. Müller, M.C. Saussele, S. Ernst, T. Machova Polakova, K. Hochhaus, A. Cross, N.C.P.

Abstract

Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1IS and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance. © 2022, The Author(s).

Published
2022

6. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR

Author

White, H, Deprez, L, Corbisier, P, Hall, V, Lin, F, Mazoua, S, Trapmann, S, Aggerholm, A, Andrikovics, H, Akiki, S, Barbany, G, Boeckx, N, Bench, A, Catherwood, M, Cayuela, J-M, Chudleigh, S, Clench, T, Colomer, D, Daraio, F, Dulucq, S, Farrugia, J, Fletcher, L, Foroni, L, Ganderton, R, Gerrard, G, Gineikiene, E, Hayette, S, El Housni, H, Izzo, B, Jansson, M, Johnels, P, Jurcek, T, Kairisto, V, Kizilors, A, Kim, D-W, Lange, T, Lion, T, Polakova, K M, Martinelli, G, McCarron, S, Merle, P A, Milner, B, Mitterbauer-Hohendanner, G, Nagar, M, Nickless, G, Nomdedéu, J, Nymoen, D A, Leibundgut, E O, Ozbek, U, Pajic, T, Pfeifer, H, Preudhomme, C, Raudsepp, K, Romeo, G, Sacha, T, Talmaci, R, Touloumenidou, T, Van der Velden, V HJ, Waits, P, Wang, L, Wilkinson, E, Wilson, G, Wren, D, Zadro, R, Ziermann, J, Zoi, K, Müller, M C, Hochhaus, A, Schimmel, H, Cross, N CP, and Emons, H

Published
2015
Full Text
View/download PDF

8. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

Author

Baccarani, M, Castagnetti, F, Gugliotta, G, Rosti, G, Soverini, S, Albeer, A, Pfirrmann, M, Bekadja, Ma, Entasoltan, B, Nachi, M, Elghandour, A, El Sorady, M, Abdelfattah, R, El Nahass, Y, Samra, M, Azzazi, M, Elsobki, E, Moussa, M, Fahmy, O, Mattar, M, Shehata, Azmy, Se, (Azmy, E, 9 ), Emad), Bolarinwa, (Bolarinwa, Ra, ( 10 ), Rahman A., Eid, (Eid, S, Samir)( 11, ), Khelif, (Khelif, A, Abderrhaim)( 11, ), Hached, (Hached, F, Farhat)( 11, ), Menif, (Menif, S, Samia)( 12, ), Rahman, (Rahman, H, Hafizur)( 13, ), Huang, (Huang, Xj, Xiaojun)(, 14, 15, ), Jiang, (Jiang, Q, Qian)(, 14, (Ye, Yx, Yuanxin)( 16, ), Zhu, (Zhu, Hl, Huanling)( 16, ), Chen, (Chen, Sn, Suning)( 17, ), Varma, (Varma, N, Neelam)( 18, ), Ganesan, (Ganesan, P, Prasanth)( 19, ), Gundeti, (Gundeti, S, Sadashivudu)( 20, ), Malhotra, (Malhotra, H, Hemant)( 21, ), Radhakrishnan, (Radhakrishnan, Vs, ( 22 ), Vivek S., Kumar, (Kumar, L, Lalit)( 23, ), Sharawat, (Sharawat, Sk, Surender Kumar)( 23, ), Seth, (Seth, T, Tulika)( 24, ), Ausekar, (Ausekar, Bv, ( 25 ), B. V., Balasubramanian, (Balasubramanian, P, Poonkuzhali)( 26, ), Poopak, (Poopak, B, Behzad)(, 27, 28, ), Inokuchi, (Inokuchi, K, Koiti)( 29, ), Kim, (Kim, Dw, Dong-Wook)( 30, ), Kindi, Al, S (Al Kindi, Salam)( 31, ), Mirasol, (Mirasol, A, Angelina)( 32, ), Qari, (Qari, M, Mohammed)( 33, ), Goh, (Goh, Yt, Yeow Tee)( 34, ), Shih, (Shih, Ly, Lee-Yung)(, 35, 36, ), Branford, (Branford, S, Susan)(, 37, 38, ), Lion, (Lion, T, Thomas)( 39, ), Valent, (Valent, P, Peter)( 40, ), Burgstaller, (Burgstaller, S, Sonja)( 41, ), Thaler, (Thaler, J, Joseph)( 41, ), Labar, (Labar, B, Boris)( 42, ), Zadro, (Zadro, R, Renata)( 42, ), Mayer, (Mayer, J, Jiri)(, 43, 44, ), Zackova, (Zackova, D, Daniela)(, 43, Faber, (Faber, E, Edgar)( 45, ), Pallisgaard, (Pallisgaard, N, Niels)( 46, ), Xavier-Mahon, (Xavier-Mahon, F, Francois)( 47, ), Lippert, (Lippert, E, Eric)( 48, ), Cayuela, (Cayuela, Jm, Jean Michel)( 49, ), Rea, (Rea, D, Delphine)( 49, ), Millot, (Millot, F, Frederic)( 50, ), Suttorp, (Suttorp, M, Meinolf)( 51, ), Hochhaus, (Hochhaus, A, Andreas)( 52, ), Niederwieser, (Niederwieser, D, Dietger)( 53, ), Saussele, (Saussele, S, Susanne)( 54, ), Haferlach, (Haferlach, T, Torsten)( 55, ), Jeromine, (Jeromine, S, Sabine)( 55, ), Panayiotidis, (Panayiotidis, P, Panayiotis)(, 56, 57, ), Conneally, (Conneally, E, Eibhlin)( 58, ), Langabeer, (Langabeer, S, Steve)( 58, ), Nagler, (Nagler, A, Arnon)(, 59, 60, ), Rupoli, (Rupoli, S, Serena)( 61, ), Santoro, (Santoro, N, Nicola)( 62, ), Albano, (Albano, F, Francesco)( 63, ), Castagnetti, (Castagnetti, F, Fausto), Ottaviani, (Ottaviani, E, Emanuela)(, 64, 65, ), Rambaldi, (Rambaldi, A, Alessandro)(, 66, 67, ), Stagno, (Stagno, F, Fabio)( 68, ), Molica, (Molica, S, Stefano)( 69, ), Biagiotti, (Biagiotti, C, Caterina)( 70, ), Scappini, (Scappini, B, Barbara)( 70, ), Lemoli, (Lemoli, R, Roberto)( 71, ), Iurlo, (Iurlo, A, Alessandra)(, 72, 73, ), Pungolino, (Pungolino, E, Ester)( 74, ), Menna, (Menna, G, Giuseppe), Pane, (Pane, F, Fabrizio)( 76, ), Gottardi, (Gottardi, E, Enrico)(, 77, 78, ), Rege-Cambrin, (Rege-Cambrin, G, Giovanna)(, 77, Binotto, (Binotto, G, Gianni)( 79, ), Putti, (Putti, Mc, Maria Caterina)( 80, ), Falzetti, (Falzetti, F, Franca)( 81, ), Visani, (Visani, G, Giuseppe)( 82, ), Galimberti, (Galimberti, S, Sara)( 83, ), Musto, (Musto, P, Pellegrino)( 84, ), Abruzzese, (Abruzzese, E, Elisabetta)( 85, ), Breccia, (Breccia, M, Massimo)( 86, ), Giona, (Giona, F, Fiorina)( 86, ), Chiusolo, (Chiusolo, P, Patrizia)( 87, ), Sica, (Sica, S, Simona)( 87, ), Fava, (Fava, C, Carmen)( 88, ), Ferrero, (Ferrero, D, Dario)( 88, ), Tiribelli, (Tiribelli, M, Mario)( 89, ), Bonifacio, (Bonifacio, M, Massimiliano)( 90, ), Griskevicius, (Griskevicius, L, Laimonas)( 91, ), Musteata, (Musteata, V, Vasile)( 92, ), Janssen, (Janssen, J, Jeroen)( 93, ), Prejzner, (Prejzner, W, Witold)( 94, ), Sacha, (Sacha, T, Tomasz)( 95, ), Waclaw, (Waclaw, J, Joanna)( 95, ), Almeida, (Almeida, Am, Antonio Medina)( 96, ), Kulikov, (Kulikov, S, Sergei)( 97, ), Turkina, (Turkina, A, Anna)( 97, ), Bogdanovic, (Bogdanovic, A, Andrija)( 98, ), Zupan, (Zupan, I, Irena)( 99, ), Marce, (Marce, S, Silvia)( 100, ), Cervantes, (Cervantes, F, Francisco)( 101, ), Steegmann, (Steegmann, Jl, Juan Luis)( 102, ), Kotlyarchuk, (Kotlyarchuk, K, Konstyantyn)( 103, ), Milner, (Milner, Bj, ( 104 ), Benedict J., Rose, (Rose, S, Susan)( 105, ), Clench, (Clench, T, Tim)( 106, ), Waits, (Waits, P, Paula)( 107, ), Austin, (Austin, S, Steve)( 108, ), Wickham, (Wickham, C, Caroline)( 109, ), Clark, (Clark, R, Richard)( 110, ), Apperley, (Apperley, J, Jane), Claudiani, (Claudiani, S, Simone)( 111, ), Foroni, (Foroni, L, Letizia)( 111, ), Szydlo, (Szydlo, R, Richard)( 111, ), Burt, (Burt, E, Emma)( 112, ), Bescoby, (Bescoby, R, Ruth)( 113, ), Cork, (Cork, L, Leanne)( 113, ), O'Brien, (O'Brien, S, Stephen)( 113, ), Green, (Green, B, Bethaney)( 114, ), Hawtree, (Hawtree, S, Sarah)( 114, ), Watson, (Watson, M, Mark)( 114, ), Bengio, (Bengio, Rm, Raquel Maria)( 115, ), Larripa, (Larripa, I, Irene)( 115, ), Pavlovsky, (Pavlovsky, C, Carolina)( 116, ), Moiraghi, (Moiraghi, B, Beatriz)( 117, ), Pinna, De, CAR (Requiao de Pinna, Cristiane Almeida)( 118, ), Magalhaes, GHR (Romani Magalhaes, Gustavo Henrique)( 119, ), Pagnano, (Pagnano, K, Katia)( 120, ), Funke, (Funke, V, Vaneuza)( 121, ), Tavares, (Tavares, Rs, Renato Sampaio)( 122, ), Prado, (Prado, A, Adriana)( 123, ), Azevedo, (Azevedo, Aa, Alita Andrade)( 124, ), Fogliatto, (Fogliatto, L, Laura)( 125, ), Bonecker, (Bonecker, S, Simone)( 126, ), Centrone, (Centrone, R, Renato)( 127, ), Moellman, (Moellman, A, Artur)( 128, ), Conchon, (Conchon, M, Monika)( 130, ), Centurion, (Centurion, Me, Maria Elida)( 131, ), (Prado, Ai, Ana-Ines)( 132, ), Lopez, (Lopez, Jl, ( 133 ), J. L., Petruzziello, (Petruzziello, F, Fara)( 75, ), Bendit, (Bendit, I, Israel), Baccarani M., Castagnetti F., Gugliotta G., Rosti G., Soverini S., Albeer A., and Pfirrmann M.

Subjects
Male, 0301 basic medicine, Cancer Research, bcr-abl, Fusion Proteins, bcr-abl, Global Health, 0302 clinical medicine, hemic and lymphatic diseases, 80 and over, Odds Ratio, Prevalence, Age Factor, Chronic, Young adult, Child, MOLECULAR RESPONSE, Leukemic, Aged, 80 and over, Leukemia, Hematology, Gene Expression Regulation, Leukemic, CHRONIC MYELOGENOUS LEUKEMIA, Age Factors, Myeloid leukemia, Middle Aged, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Female, Life Sciences & Biomedicine, Human, Adult, Transcriptional Activation, medicine.medical_specialty, Adolescent, Immunology, IMATINIB MESYLATE, DENDRITIC CELLS, CML PATIENTS, Young Adult, 03 medical and health sciences, Myelogenous, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, 1112 Oncology and Carcinogenesis, BCR/ABL TRANSCRIPT, Preschool, CYTOGENETIC RESPONSE, Aged, Science & Technology, CHRONIC-PHASE, business.industry, Infant, Newborn, Fusion Proteins, ABL FUSION PROTEINS, P190 BCR-ABL, Infant, 1103 Clinical Sciences, Odds ratio, Newborn, medicine.disease, International BCR-ABL Study Group, Settore MED/15 - MALATTIE DEL SANGUE, 030104 developmental biology, Imatinib mesylate, Gene Expression Regulation, BCR-ABL Positive, business, Chronic myelogenous leukemia
Abstract

There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia. Their frequency has never been systematically investigated. In a series of 45503 newly diagnosed CML patients reported from 45 countries, it was found that the proportion of e13a2 (also known as b2a2) and of e14a2 (also known as b3a2), including the cases co-expressing e14a2 and e13a2, was 37.9% and 62.1%, respectively. The proportion of these two transcripts was correlated with gender, e13a2 being more frequent in males (39.2%) than in females (36.2%), was correlated with age, decreasing from 39.6% in children and adolescents down to 31.6% in patients ≥ 80 years old, and was not constant worldwide. Other, rare transcripts were reported in 666/34561 patients (1.93%). The proportion of rare transcripts was associatedwith gender (2.27% in females and 1.69% in males) and with age (from 1.79% in children and adolescents up to 3.84% in patients ≥ 80 years old). These data show that the differences in proportion are not by chance. This is important, as the transcript type is a variable that is suspected to be of prognostic importance for response to treatment, outcome of treatment, and rate of treatment-free remission.

Published
2019
Full Text
View/download PDF

9. Establishment of the WHO 2nd International Standard Factor V, plasma (16/374): communication from the SSC of the ISTH

Author

Hubbard, Anthony R., Thelwell, Craig, Rigsby, Peter, Baker, P., Beavis, J., Gebauer, R., Riddell, A., Park, S., Jung, K., Kaar, W., Rosen, S., Bryngelhed, P., Mackie, I, Young, B., Stroobants, A., Hunfeld, A., Kusch, M., Praefcke, G., Rosenkranz, S., Schroda, A., Moore, G., Dunsmore, C., Zadro, R., Lawrence, C., Bevan, S., Foulon, D., Teramura, G., Bowyer, A., Kitchen, S., Doyle, M., Binder, N., Ovanesov, M., Liang, Y., Surov, S., Parunov, L., Rigano, J., Gottschalk, N., Demaistre, E., Peyvandi, F., Novembrino, C., Jeanpierre, E., Grenet, J., Aime, C., Maes, Marie-Berthe, Sidelmann, J., Martineau, N., Grimaux, M., Johnson, L., and Subcomm Factor VIII Factor IX Rare

Subjects
medicine.medical_specialty, biology, business.industry, International standard, MEDLINE, Factor V, Reproducibility of Results, Guidelines as Topic, Hematology, Reference Standards, World Health Organization, Predictive Value of Tests, Predictive value of tests, biology.protein, Humans, Medicine, Medical physics, Blood Coagulation Tests, Human medicine, business, Blood Coagulation, Reference standards, Biomarkers
Published
2019
Full Text
View/download PDF

22. High levels of FVIII and Von Willebrand Factor in chronic Graft-versus-Host Disease patients

Author

Pulanic D, Samardzic A, Desnica L, Zadro R, Milošević M, Serventi Seiwerth R, Durakovic N, Peric Z, Coen Herak D, Milos M, Kraljevic L, Mravak Stipetic M, Bilic E, Ceovic R, Klepac Pulanic T, Petricek I, Saban N, Zelic Kerep A, Ljubas Kelecic D, Vukic T, Mazic S, Bojanic I, Bilić E, Batinic D, Vrhovac R, Pavletic SZ and Mohammad Mohty, Hillard M. Lazarus

Subjects
chronic graft versus host disease, von Willebrand, factor VIII
Abstract

Studija razina von Willebrandova faktora i faktora 8 u bolesnika sa kroničnim GVHD-om.

Published
2019

23. Acute promyelocytic leukemia after whole brain irradiation of primary brain lymphomainan HIV-infected patient

Author

Boban A, Radman I, Zadro R, Dubravcic K, Maretic T, Civljak R, Lisic M, and Begovac J

Subjects
HIV, acute promyelocytic leukemia, primary central nervous system lymphoma, Medicine
Abstract

Abstract The occurrence of acute promyelocytic leukemia (APL) in HIV-infected patients has been reported in only five cases. Due to a very small number of reported HIV/APL patients who have been treated with different therapies with the variable outcome, the prognosis of APL in the setting of the HIV-infection is unclear. Here, we report a case of an HIV-patient who developed APL and upon treatment entered a complete remission. A 25-years old male patient was diagnosed with HIV-infection in 1996, but remained untreated. In 2004, the patient was diagnosed with primary central nervous system lymphoma. We treated the patient with antiretroviral therapy and whole-brain irradiation, resulting in complete remission of the lymphoma. In 2006, prompted by a sudden neutropenia, we carried out a set of diagnostic procedures, revealing APL. Induction therapy consisted of standard treatment with all-trans-retinoic-acid (ATRA) and idarubicin. Subsequent cytological and molecular analysis of bone marrow demonstrated complete hematological and molecular remission. Due to the poor general condition, consolidation treatment with ATRA was given in March and April 2007. The last follow-up 14 months later, showed sustained molecular APL remission. In conclusion, we demonstrated that a complete molecular APL remission in an HIV-patient was achieved by using reduced-intensity treatment.

Published
2009
Full Text
View/download PDF

25. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Author

Cross, N.C.P. White, H.E. Ernst, T. Welden, L. Dietz, C. Saglio, G. Mahon, F.-X. Wong, C.C. Zheng, D. Wong, S. Wang, S.-S. Akiki, S. Albano, F. Andrikovics, H. Anwar, J. Balatzenko, G. Bendit, I. Beveridge, J. Boeckx, N. Cerveira, N. Cheng, S.-M. Colomer, D. Czurda, S. Daraio, F. Dulucq, S. Eggen, L. El Housni, H. Gerrard, G. Gniot, M. Izzo, B. Jacquin, D. Janssen, J.J.W.M. Jeromin, S. Jurcek, T. Kim, D.-W. Machova-Polakova, K. Martinez-Lopez, J. McBean, M. Mesanovic, S. Mitterbauer-Hohendanner, G. Mobtaker, H. Mozziconacci, M.-J. Pajič, T. Pallisgaard, N. Panagiotidis, P. Press, R.D. Qin, Y.-Z. Radich, J. Sacha, T. Touloumenidou, T. Waits, P. Wilkinson, E. Zadro, R. Müller, M.C. Hochhaus, A. Branford, S.

Subjects
hemic and lymphatic diseases
Abstract

Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized to the International Scale (IS) is key to proper disease management, especially when treatment cessation is considered. Most laboratories currently use a time-consuming sample exchange process with reference laboratories for IS calibration. A World Health Organization (WHO) BCR-ABL1 reference panel was developed (MR 1 -MR 4), but access to the material is limited. In this study, we describe the development of the first cell-based secondary reference panel that is traceable to and faithfully replicates the WHO panel, with an additional MR 4.5 level. The secondary panel was calibrated to IS using digital PCR with ABL1, BCR and GUSB as reference genes and evaluated by 44 laboratories worldwide. Interestingly, we found that >40% of BCR-ABL1 assays showed signs of inadequate optimization such as poor linearity and suboptimal PCR efficiency. Nonetheless, when optimized sample inputs were used, >60% demonstrated satisfactory IS accuracy, precision and/or MR 4.5 sensitivity, and 58% obtained IS conversion factors from the secondary reference concordant with their current values. Correlation analysis indicated no significant alterations in %BCR-ABL1 results caused by different assay configurations. More assays achieved good precision and/or sensitivity than IS accuracy, indicating the need for better IS calibration mechanisms. © 2016 Macmillan Publishers Limited, part of Springer Nature.

Published
2016

26. Kronična bolest presatka protiv primatelja u KBC Zagreb – stručni i znanstveno-istraživački izazovi

Author

Pulanić, D., Desnica, L., Serventi-Seiwerth, R., Mravak-Stipetić, M., Bilić, E., Čeović, R., Matić, N., Duraković, N., Perić, Z., Rajić, Lj., Klepac Pulanić, T., Petriček, I., Ljubas Kelečić, D., Vukić, T., Alerić, I., Dušek D., Matić, T., Bojanić, I., Mazić, S., Prenc, E., Prah, I., Grce, M., Batinić, D., Zadro, R., Vrhovac, R., Pavletić, S. Ž., and Nemet D.

Subjects
kronična bolest presatka protiv primatelja
Abstract

Kronična bolest presatka protiv primatelja (eng.Chronic Graft versus Host Disease - cGVHD) najvažnija je kasna komplikacija nakon transplantacije alogeničnih krvotvornih matičnih stanica (aloTKMS) i vodeći uzrok morbiditeta i mortaliteta koji nije povezan s relapsom osnovne bolesti u osoba nakon aloTKMS- a. U ovom izdanju opisuju se rezultati i aktivnosti multidisciplinarnog tima za cGVHD osnovanog 2013. godine na KBC Zagreb.

Published
2016

28. Daljnji napredak multidisciplinarnog tima za liječenje kronične bolesti presatka protiv primatelja i kasnih komplikacija nakon transplantacije krvotvornih matičnih stanica u KBC Zagreb

Author

Desnica, L., Pulanić, D., Serventi-Seiwerth, R., Mravak-Stipetić, M., Bilić, E., Čeović, R., Matić, N., Rajić, Lj., Duraković, N., Perić, Z., Klepac Pulanić, T., Petriček, I., Ljubas Kelečić, D., Vukić, T., Dušek, D., Bojanić, I., Mazić, S., Prenc, Ema, Prah, I.O., Grce, M., Batinić, D., Zadro, R., Vrhovac, R., Pavletić, S.Ž., and Nemet, D.

Subjects
multidisciplinarnog tim, kasne komplikacije, kronična bolest presatka protiv primatelja
Abstract

Danas se u svijetu sve veći broj bolesnika s malignim i nemalignim bolestima liječi transplantacijom alogeničnih krvotvornih matičnih stanica (aloTKMS). Kronična bolest presatka protiv primatelja (eng. Chronic graft versus host disease - cGVHD) vodeći je uzrok morbiditeta i mortaliteta koji nije povezan s relapsom osnovne bolesti u osoba nakon aloTKMS‑a. Na KBC Zagreb u 2013. godini formiran je multidisciplinarni tim za liječenje cGVHD-a i dugotrajnih komplikacija nakon aloTKMS-a u suradnji s National Cancer Institute (NCI), NIH, SAD.

Published
2015

29. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Author

Cross, N C P, primary, White, H E, additional, Ernst, T, additional, Welden, L, additional, Dietz, C, additional, Saglio, G, additional, Mahon, F-X, additional, Wong, C C, additional, Zheng, D, additional, Wong, S, additional, Wang, S-S, additional, Akiki, S, additional, Albano, F, additional, Andrikovics, H, additional, Anwar, J, additional, Balatzenko, G, additional, Bendit, I, additional, Beveridge, J, additional, Boeckx, N, additional, Cerveira, N, additional, Cheng, S-M, additional, Colomer, D, additional, Czurda, S, additional, Daraio, F, additional, Dulucq, S, additional, Eggen, L, additional, El Housni, H, additional, Gerrard, G, additional, Gniot, M, additional, Izzo, B, additional, Jacquin, D, additional, Janssen, J J W M, additional, Jeromin, S, additional, Jurcek, T, additional, Kim, D-W, additional, Machova-Polakova, K, additional, Martinez-Lopez, J, additional, McBean, M, additional, Mesanovic, S, additional, Mitterbauer-Hohendanner, G, additional, Mobtaker, H, additional, Mozziconacci, M-J, additional, Pajič, T, additional, Pallisgaard, N, additional, Panagiotidis, P, additional, Press, R D, additional, Qin, Y-Z, additional, Radich, J, additional, Sacha, T, additional, Touloumenidou, T, additional, Waits, P, additional, Wilkinson, E, additional, Zadro, R, additional, Müller, M C, additional, Hochhaus, A, additional, and Branford, S, additional

Published
2016
Full Text
View/download PDF

30. Croatian CML Registry based on European LeukemiaNet CML Registry

Author

Serić, D, Perić, Z, Sinčić-Petričević, J, Lozić, D, Mandac-Rogulj, I, Duletić Naćinović, A, Gverić-Krečak, V, Ćorović-Arneri, E, Pejsa, V, Suvić-Križanić, V, Škunca, Z, Babok-Flegarić, R, Krmek-Županić, D, Čarzavec, D, Lazić-Prodan, V, Coha, Božena, Ajduković, R, Romić, I, Zadro, R, Davidović, S, Lasan-Trčić, R, and Labar, R

Subjects
hemic and lymphatic diseases, CML Registry, European LeukemiaNet
Abstract

According to data collected so far the incidence of CML in Croatia is 0.99 / 100 000 inhabitants. There is uneven incidence distribution of CML by region, but due to the small number of patients we need a longer follow-up. Participation in ELN Registry study clearly improved the diagnostic possibilities (use of quantitative PCR for monitoring of CML). We also implemented for most patients ELN recommendations for treatment response with TKI.

Published
2011

31. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR

Author

White, H., Deprez, L., Corbisier, P., Hall, V., Lin, F., Mazoua, S., Trapmann, S., Aggerholm, A., Andrikovics, H., Akiki, S., Barbany, G., Boeckx, N., Bench, A., Catherwood, M., Cayuela, J-M, Chudleigh, S., Clench, T., Colomer, D., Daraio, F., Dulucq, S., Farrugia, J., Fletcher, L., Foroni, L., Ganderton, R., Gerrard, G., Gineikiene, E., Hayette, S., El Housni, H., Izzo, B., Jansson, Mattias, Johnels, P., Jurcek, T., Kairisto, V., Kizilors, A., Kim, D-W, Lange, T., Lion, T., Polakova, K. M., Martinelli, G., McCarron, S., Merle, P. A., Milner, B., Mitterbauer-Hohendanner, G., Nagar, M., Nickless, G., Nomdedeu, J., Nymoen, D. A., Leibundgut, E. O., Ozbek, U., Pajic, T., Pfeifer, H., Preudhomme, C., Raudsepp, K., Romeo, G., Sacha, T., Talmaci, R., Touloumenidou, T., Van der Velden, V. H. J., Waits, P., Wang, L., Wilkinson, E., Wilson, G., Wren, D., Zadro, R., Ziermann, J., Zoi, K., Mueller, M. C., Hochhaus, A., Schimmel, H., Cross, N. C. P., Emons, H., White, H., Deprez, L., Corbisier, P., Hall, V., Lin, F., Mazoua, S., Trapmann, S., Aggerholm, A., Andrikovics, H., Akiki, S., Barbany, G., Boeckx, N., Bench, A., Catherwood, M., Cayuela, J-M, Chudleigh, S., Clench, T., Colomer, D., Daraio, F., Dulucq, S., Farrugia, J., Fletcher, L., Foroni, L., Ganderton, R., Gerrard, G., Gineikiene, E., Hayette, S., El Housni, H., Izzo, B., Jansson, Mattias, Johnels, P., Jurcek, T., Kairisto, V., Kizilors, A., Kim, D-W, Lange, T., Lion, T., Polakova, K. M., Martinelli, G., McCarron, S., Merle, P. A., Milner, B., Mitterbauer-Hohendanner, G., Nagar, M., Nickless, G., Nomdedeu, J., Nymoen, D. A., Leibundgut, E. O., Ozbek, U., Pajic, T., Pfeifer, H., Preudhomme, C., Raudsepp, K., Romeo, G., Sacha, T., Talmaci, R., Touloumenidou, T., Van der Velden, V. H. J., Waits, P., Wang, L., Wilkinson, E., Wilson, G., Wren, D., Zadro, R., Ziermann, J., Zoi, K., Mueller, M. C., Hochhaus, A., Schimmel, H., Cross, N. C. P., and Emons, H.

Abstract

Serial quantification of BCR-ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR-ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08 +/- 0.13 x 10(6), 1.08 +/- 0.11 x 10(5), 1.03 +/- 0.10 x 10(4), 1.02 +/- 0.09 x 10(3), 1.04 +/- 0.10 x 10(2) and 10.0 +/- 1.5 copies/mu l. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR-ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR-ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/;CRM code ERM-AD623a-f).

Published
2015
Full Text
View/download PDF

32. Reliability of Prothrombin and Activated Partial Thromboplastin Time Determation on CoaguChek Pro DM

Author

Milos, M., Coen, D., and Zadro, R.

Subjects
CoaguChek Pro DM, point-of-care, prothrombin time (PT), activated partial thromboplastin time (aPTT), circulatory and respiratory physiology
Abstract

The authors evaluated the reliability of prothrombin time (PT) and activated partial thromboplastin time (aPTT) determination on a bedside coagulation monitor (CoaguChek Pro DM ; Roche Diagnostics, Germany). Measurement of PT and aPTT was performed in 54 specimens and was compared with reference laboratory methods. The obtained values for PT and aPTT in healthy subjects on CoaguChek were close to the reference interval established by the manufacturer, as well as the laboratory reference interval. Despite the good correlation coefficients for PT (r = 0.958) and aPTT (r = 0.885), there was an important dispersion of values between 2 methods as shown by Bland and Altman plots. In the group of 19 patients on oral anticoagulant therapy, comparable values were observed in 14 cases, whereas discrepancy between 5 results could lead to a different therapeutic decision. CoaguChek aPTT determination was shown to be a good method for monitoring unfractionated heparin therapy. However, the results should not be compared with each other, and the same technique should always be chosen to monitor patients.

Published
2004

33. A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

Author

White, H, primary, Deprez, L, additional, Corbisier, P, additional, Hall, V, additional, Lin, F, additional, Mazoua, S, additional, Trapmann, S, additional, Aggerholm, A, additional, Andrikovics, H, additional, Akiki, S, additional, Barbany, G, additional, Boeckx, N, additional, Bench, A, additional, Catherwood, M, additional, Cayuela, J-M, additional, Chudleigh, S, additional, Clench, T, additional, Colomer, D, additional, Daraio, F, additional, Dulucq, S, additional, Farrugia, J, additional, Fletcher, L, additional, Foroni, L, additional, Ganderton, R, additional, Gerrard, G, additional, Gineikienė, E, additional, Hayette, S, additional, El Housni, H, additional, Izzo, B, additional, Jansson, M, additional, Johnels, P, additional, Jurcek, T, additional, Kairisto, V, additional, Kizilors, A, additional, Kim, D-W, additional, Lange, T, additional, Lion, T, additional, Polakova, K M, additional, Martinelli, G, additional, McCarron, S, additional, Merle, P A, additional, Milner, B, additional, Mitterbauer-Hohendanner, G, additional, Nagar, M, additional, Nickless, G, additional, Nomdedéu, J, additional, Nymoen, D A, additional, Leibundgut, E O, additional, Ozbek, U, additional, Pajič, T, additional, Pfeifer, H, additional, Preudhomme, C, additional, Raudsepp, K, additional, Romeo, G, additional, Sacha, T, additional, Talmaci, R, additional, Touloumenidou, T, additional, Van der Velden, V H J, additional, Waits, P, additional, Wang, L, additional, Wilkinson, E, additional, Wilson, G, additional, Wren, D, additional, Zadro, R, additional, Ziermann, J, additional, Zoi, K, additional, Müller, M C, additional, Hochhaus, A, additional, Schimmel, H, additional, Cross, N C P, additional, and Emons, H, additional

Published
2014
Full Text
View/download PDF

35. LIJEČENJE KRONIČNE MIJELOIČNE LEUKEMIJE U UZNAPREDOVALOJ FAZI BOLESTI IMATINIB MESILATOM LIJEČENJE KRONIČNE MIJELOIČNE LEUKEMIJE U UZNAPREDOVALOJ FAZI BOLESTI IMATINIB MESILATOM

Author

Bulum, Joško, Labar, Boris, Mikulić, Mirta, Bogdanić, Vinko, Sertić, Dubravka, Nemet, Damir, Krečak-Gverić, V, Kovačević, Jasna, Serventi-Seiwerth, Ranka, Mrsić-Davidović, Sanja, Zadro, R, and Boban, D.

Subjects
Kronična mijeloična leukemija – citostatsko liječenje, Philadelphia kromosom, Fuzijske bjelančevine, bcr/abl – inhibitori, Citogenetika, Krvna slika, Citostatici – nuspojave
Abstract

UVOD: Philadelphia kromosom pozitivna kronična mijeloična leukemija (Ph+ KML) u uznapredovaloj fazi bolesti rezistentna je na uobičajeno citostatsko liječenje. Imatinib mesilat pokazao se vrlo djelotvornim u tih bolesnika. U radu su prikazani preliminarni rezultati. BOLESNICI I METODE: Tijekom 9 mjeseci imatinib mesilatom liječeno je 15 bolesnika, 9 u ubrzanoj fazi bolesti i 6 u blastičnoj krizi. Terapijski učinak određen je hematološkim i citogenetskim odgovorom. REZULTATI: Kompletna hematološka remisija postignuta je u 12 bolesnika (80%). Citogenetski odgovor utvrđen je u 8 bolesnika (53%) od čega u 6 bolesnika (40%) dobar citogenetski odgovor. Tijekom 9 mjeseci liječenja u 9 bolesnika (60%) je došlo do progresije bolesti zbog čega su 4 bolesnika umrla. Najčešće nuspojave liječenja su edemi, mučnina, neutropenija i trombocitopenija. ZAKLJUČCI: Liječenjem imatinib mesilatom postignut je dobar, ali kratkotrajan, učinak u ubrzanoj fazi i blastičnoj krizi Ph+ KML.

Published
2003

36. TEL/AML 1 fusion gene ; prevalence and immunophenotypic characteristics of positive cells in childhood acute lymphoblastic leukemia

Author

Golemović, M., Zadro, R., Batinić, Drago, Vojnović, G., Konja, Josip, and Labar, Boris

Subjects
hemic and lymphatic diseases, neoplasms, TEL/AML1, fusion, gene, leukemia
Abstract

TEL/AML1 fusion gene is one of the most common non-random genetic aberations in precursor B cell acute lymphoblasatic leukemia in childhood and is considered as independent good prognostic factor. In the present study we have analyzed the immunophenotype of leukemic cells and the presence of tel/aml1 fusion transcript in RNA samples in 20 children with ALL.

Published
2001

37. Expression of cyclin A1 in acute leukaemia

Author

Golemović, M., Boban, Dubravka, Sučić, Mirna, Ries, Sanja, Zadro, R., Bogdanić, Vinko, Nemet, Damir, Mrsić, Mirando, Labar, Boris, Rajić, Ljubica, Femenić, Ranka, Konja, Josip, Batinić, Drago, and Labar, Boris

Subjects
expression, cyclin A1, acute leukemia, hemic and lymphatic diseases
Abstract

The expression of cyclin A1, a cell cycle regulatory protein, has been documewnted in normal human hematopoietic progenitor cells and in the majority of myeloid and undifferentiated hematological malignancies.In this work we extended this observation by analysing the expression of cyclin A1 in 38 acute leukaemias of myeloid, lymphoid and mixed lineage leukaemias in children and adults.

Published
2001

38. AKUTNA LEUKEMIJA SA ZRNCIMA- PRIKAZ SLUČAJA

Author

Ries, S., Boban, D., Marković-Glamočak, M., Sučić, M., Gjadrov-Kuveždić, K., Batinić, D., Mrsić, S., Zadro, R., Šćukanec-Špoljar, M., and Labar, B.

Subjects
AML, citomorfologija, imunofenotip, citogenetika
Abstract

Bolesnik je upućen u Zavod za hematologiju s dijagnozom akutne mijeloične leukemije. Pri primitku je punktirana koštana srž i uzeti su uzorci za citomorfologiju, imunotipizaciju, citogenetiku, molekularnu analizu i ultrastrukturnu analizu. Citomorfološki su nađeni blasti sa sitnim, brojnim, crvenkastim granulama. Učinjena su citokemijska bojenja. Blasti su bili MPO, sudan i ANAE negativni, a PAS pozitivni. Metakromatsko bojenje toluidinom se prikazalo nespecifično. Imunocitokemijski su limfatični biljezi bili pozitivni u većini blasta. Nalaz imunotipizacije prikazu je neoplazmu prekursora B-stanica imunofenotipa "common-ALL" uz koekspresiju mijeloidnih biljega. Nalaz citogenetike isključuje t (15 ; 17).

Published
2000

39. PCR in situ u dijagnostici akutne mijeloične leukemije sa sazrijevanjem

Author

Gjadrov-Kuveždić, K., Sučić, M., Boban, D., Marković-Glamočak, M., Ries, S., Zadro, R., Batinić, D., Mrsić, S., Stavljenić-Rukavina, A., and Labar, B.

Subjects
PCR in situ, t(8, 12), fuzijski gen AML1/ETO
Abstract

Klasifikacija Svjetske zdravstvene organizacije o mijeloidnim i limfoidnim neoplazmama uključuje akutne mijeloične leukemije koje nose t(8 ; 21), t(15 ; 17), inv(16) i preuredbe gena MLL na kromosomu 11 u zasebne podskupine. Velika je klinička važnost prepoznati bolesnike, koji imaju kriterije za svrstavanje u te podskupine akutnih mijeloičnih leukemija, jer oni u pravilu pokazuju bolji odgovor na terapiju, brži ulazak u remisiju bolesti, a time i dulje preživljenje.Citomorfološki i citokemijski nalaz osnova je dijagnoze akutnih leukemija, no PCR-om in situ moguće je dijagnosticirati i leukemije koje osim prepoznatljivog morfološkog fenotipa sadrže i promjene genoma. U našem istraživanju analizirali smo 21 bolesnika s citomorfološki i citokemijski dijagnosticiranom akutnom mijeloičnom leukemijom sa znacima sazrijevanja (M2 prema FAB-u), i primjenom PCR-a in situ dijagnosticirali 5 leukemija pozitivnih na t(8 ; 21). Translokacija uvjetuje stvaranje fuzijskog gena AML1/ETO. PCR-om in situ također smo pratili bolesnike pozitivne na AML1/ETO i tijekom remisije bolesti, što nam je omogućilo razlikovanje malignih nezrelih stanica od nezrelih stanica normalne hematopoeze, koje nastaju tijekom oporavka koštane srži. Primjena PCR-a in situ, kao morfološke molekularne metode, povećava osjetljivost citomorfološke analize.

Published
2000

41. ATRA and anthracyclines in the treatment of acute promyelocytic leukaemia

Author

Aurer, I, Labar, B, Zadro, R, Nemet, D, Mrsić, S, Bogdanić, V, Mrsić, M, Radman, I, Sertić, D, Šalek-Zupančić, Silva, Kovačević-Metelko, J, and Stavljenić-Rukavina, A.

Subjects
hemic and lymphatic diseases, organic chemicals, ATRA, acute promyelocytic leukemia, neoplasms, biological factors
Abstract

ATRA and anthracyclines in the treatment of acute promyelocytic leukaemia

Published
1998

43. Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial.

Author

Aslanyan, M. G, primary, Langemeijer, S. M.C., additional, Cilloni, D., additional, Saglio, G., additional, Marie, JP, additional, Tang, R., additional, Labar, B., additional, Zadro, R., additional, Batinic, D., additional, Amadori, S., additional, Lo Coco, F., additional, Scheele, T., additional, Kroeze, L., additional, Massop, M., additional, van Hoogen, P., additional, Stevens, E., additional, Muus, P., additional, Suciu, S., additional, Baila, L., additional, Marijt, E. W.A., additional, Willemze, R., additional, de Witte, T., additional, van der Reijden, B., additional, and Jansen, J. H., additional

Published
2009
Full Text
View/download PDF

48. P015 Outcome in a small series of biphenotypic acute leukemia (BAL) patients

Author

Mikulic, M., primary, Batinić, D., additional, Rnjak, L., additional, Mrsić, M., additional, Nemet, D., additional, Serventi-Seiwerth, R., additional, Sertić, D., additional, Dubravčić, K., additional, Golemović, M., additional, Mrsić, S., additional, Sučić, M., additional, Gjadrov, K., additional, Zadro, R., additional, and Labar, B., additional

Published
2007
Full Text
View/download PDF

49. P094 Autologous blood stem cell (PBSCT) vs bone marrow transplantation (ABMT) for acute myeloid leukaemia in 1st remission

Author

Duraković, N., primary, Nemet, D., additional, Sertić, D., additional, Mrsić, M., additional, Golubić-Ćepulić, B., additional, Bojanić, I., additional, Batinić, D., additional, Serventi-Seiwerth, R., additional, Mazić, S., additional, Zadro, R., additional, Mrsić-Davidović, S., additional, and Labar, B., additional

Published
2007
Full Text
View/download PDF

50. P009 Improved therapeutic outcome in children with acute lymphoblastic leukemia in Croatia

Author

Konja, J., primary, Rajić, Lj., additional, Femenić, R., additional, Ćulić, S., additional, Roganović, J., additional, Hajnžić, T.F., additional, Batinić, D., additional, Sučić, M., additional, Lasan-Trčić, R., additional, Zadro, R., additional, Bilić, E., additional, Smokvina, M., additional, Armanda, V., additional, Kuljiš, D., additional, Jakovljević, G., additional, and Aničić, M., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results